NCT03266159 2017-12-08A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid TumorsGlaxoSmithKlinePhase 2 Withdrawn